On May 31, 2026, our board of directors approved a restructuring plan to significantly reduce our operating expenses and preserve capital.

filing / Jul 30, 2026 / receipt

The restructuring plan reduced our workforce by approximately 85%, from 57 to nine full-time employees, and was substantially completed during the second quarter of 2026.

filing / Jul 30, 2026 / receipt

Restructuring charges were $4.3 million for the three months ended June 30, 2026, compared to zero for the three months ended June 30, 2025.

filing / Jul 30, 2026 / receipt

• $0.1 million of increased employee compensation costs due to increased headcount, including a $0.6 million increase in stock-based compensation expense, partially offset by decreased headcount; and

filing / Jul 30, 2026 / receipt

We recently implemented a workforce reduction following our discontinuation of further development of pociredir, and have had executive transitions, including of our chief executive officer, chief financial officer, president of research and development, chief scientific officer, and chief medical officer in the past.

filing / Jul 30, 2026 / receipt

We recently implemented a restructuring plan to significantly reduce our operating expenses and preserve capital following the discontinuation of development of pociredir for the treatment of SCD.

filing / Jul 30, 2026 / receipt